Top Markets
Coin of the day
Bioqual, Inc. Bioqual, Inc.

Bioqual, Inc.

BIOQ
Rank in Stocks #28015
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing... Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue. Furthermore, their work extends to malaria, hepatitis, and oncology. The firm's comprehensive laboratory capabilities further include processing biological samples, producing virus stocks, precisely quantifying infectious viral loads, and conducting assays like virus neutralization and hemagglutination inhibition. They also utilize advanced techniques such as quantitative PCR, ELISA for antigen and antibody detection, flow cytometry, lymphocyte proliferation studies, and various other cell-based analytical methods. Moreover, Bioqual furnishes specialized support for studies employing animal research models. Established in 1981, Bioqual, Inc. maintains its primary operational base in Rockville, Maryland.
Share Price
$32.50
Last synced: 2026-08-18
Market Cap
$29.07M
Change (1 day)
0.00%
Change (1 year)
-24.75%
Country
US
Trade Bioqual, Inc. (BIOQ)

Category

Earnings for Bioqual, Inc. (BIOQ)
Earnings in 2026 TTM: 0
According to Bioqual, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Bioqual, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US